CTRV - ContraVir Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.7500
-0.1000 (-2.60%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.8500
Open3.8900
Bid0.0000 x 4000
Ask0.0000 x 4000
Day's Range3.6521 - 3.9200
52 Week Range3.5200 - 91.0000
Volume213,366
Avg. Volume827,425
Market Cap6.154M
Beta (3Y Monthly)-0.12
PE Ratio (TTM)N/A
EPS (TTM)-81.8950
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • GlobeNewswire20 days ago

    ContraVir Pharmaceuticals Submits IND Application for CRV431 for NASH

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced the filing of an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for CRV431 for the treatment of NASH.

  • Benzinga26 days ago

    Advice For New Traders When Momentum Dries Up

    The loss of momentum is unfortunate, but not devastating. Part of making a career of day trading is understanding that swings in momentum like this happen, and traders need to be prepared for dry spells. The first step in finding balance while momentum disappears is recognizing when reliable trading setups become less reliable.

  • Benzinga26 days ago

    ContraVir Rebounds From Record Low On Positive FDA Feedback

    ContraVir Pharmaceuticals Inc (NASDAQ: CTRV) shares have been highly volatile of late, with the promise offered by its non-alcoholic steatohepatitis drug cushioning any downside for the stock. ContraVir, a thinly traded nanocap biotech, said Thursday after the close the FDA has given it positive feedback in response to its pre-IND meeting about its NASH pipeline asset CRV431. The positive feedback pertained to preclinical data for CRV431, with the regulatory body agreeing with ContraVir's proposed plan for further preclinical studies to support the development of the asset.

  • MarketWatch26 days ago

    ContraVir's stock rockets off record low after 'positive feedback' on pre-IND for NASH

    Shares of ContraVir Pharmaceuticals Inc. rocketed 69% in active premarket trading Friday, to bounce off the previous session's record low close, after the biopharmaceutical company said it received "positive feedback" from the U.S. Food and Drug Administration in response to its pre-Investigational New Drug (pre-IND) meeting. Trading volume ballooned to over 760,000 shares, compared with the full-day average of about 1 million shares. The pre-IND meeting was with respect to the development of CRV431 for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH). The company said the feedback supports an IND submission for CRV431. "This IND submission for NASH will be in addition to our current existing IND for hepatitis B virus treatment," Chief Executive Robert Foster said. The stock has plunged 78% year to date through Thursday, while the iShares Nasdaq Biotechnology ETF has gained 13% and the S&P 500 has advanced 18%.

  • Benzinga26 days ago

    The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 20) Abbott Laboratories (NYSE: ABT ) ANI Pharmaceuticals ...

  • ContraVir’s stock suffers record plunge after seesaw week of upbeat drug studies, mistaken filings and withdrawals of withdrawals
    MarketWatch28 days ago

    ContraVir’s stock suffers record plunge after seesaw week of upbeat drug studies, mistaken filings and withdrawals of withdrawals

    Shares of ContraVir Pharmaceuticals Inc. suffered a record Tuesday, to cap off a whipsaw week for investors that included upbeat results of a drug study, filings indicating the withdrawal, and a withdrawal of the withdrawal, of a share offering.

  • GlobeNewswire29 days ago

    ContraVir Pharmaceuticals, Inc. Announces Pricing of $15.6 Million Public Offering

    ContraVir Pharmaceuticals, Inc. (“ContraVir,” the “Company,” “we,” “our” or “us”) (CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, today announced the pricing of a public offering with expected total gross proceeds of approximately $15.6 million, before deducting placement agent fees and other offering expenses payable by the Company. Roth Capital Partners is acting as the lead placement agent for the offering. Arcadia Securities, LLC is acting as co-placement agent for the offering.

  • Benzingalast month

    ContraVir Moves Higher After NASH Drug Shows 100% Efficacy In Fibrosis Prevention

    ContraVir Pharmaceuticals Inc (NASDAQ: CTRV ) shares were rallying Monday on positive news related to its non-alcoholic steatohepatitis, or NASH, drug. ContraVir, which came under pressure Friday following ...

  • GlobeNewswirelast month

    Compelling Positive Results Reported from Human Liver Experiments with ContraVir Pharmaceuticals’ NASH Drug Candidate

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced findings from its first study with human precision cut liver slice cultures. Liver disease was simulated in this unique experimental model by application of the potent, profibrotic molecules, TGFβ and PDGF.

  • Benzingalast month

    Why Low-Float, Thinly Traded ContraVir Pharma's Rally Is Continuing

    June has been an eventful month for  ContraVir Pharmaceuticals Inc (NASDAQ: CTRV ). Close on the heels of a 1-for-70 reverse stock split, which became effective June 3, the company has had incremental ...

  • GlobeNewswirelast month

    ContraVir Pharmaceuticals Announces Publication of CRV431 Data from Experimental Model of Hepatitis B

    EDISON, N.J., June 11, 2019 -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of.

  • Why ContraVir Pharmaceuticals (CTRV) Is Skyrocketing Today
    InvestorPlacelast month

    Why ContraVir Pharmaceuticals (CTRV) Is Skyrocketing Today

    ContraVir Pharmaceuticals (NASDAQ:CTRV) had a memorable Friday as the company's stock soared off the heels of a successful results regarding one of its treatments for liver disease.Source: Shutterstock The Edison, New Jersey-based pharmaceutical business today unveiled findings from a preclinical study in which CRV431, which is a novel cyclophilin inhibitor, significantly helped to decrease the extent of fibrosis in a second animal model of liver fibrosis. The term fibrosis refers to scarring of the liver, and it is a common symptom of non-alcoholic steatohepatitis (NASH), which causes impaired liver function.ContraVir Pharmaceuticals focuses mostly on developing therapeutic drugs to treat liver disease that arises from NASH. The company said that obeticholic acid (OCA), which is a semi-synthetic bile acid analogue drug, was approved for the treatment of primary biliary cholangitis (PBC), and it is being evaluated in Phase 3 trials by another company.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe medication was used by a comparator drug within the study and did not decrease the extent of fibrosis in this study conducted by the company. This industry-standard model requires liver fibrosis to be induced in mice by administering carbon tetrachloride."This is the second animal model, and the fifth study overall, in which CRV431 consistently demonstrated a statistically significant reduction in fibrosis," said Dr. Robert Foster, Chief Executive Officer of ContraVir. "In addition, this study showed that CRV431 reduced fibrosis where OCA, a drug approved for PBC with potential to treat additional liver diseases, such as NASH, did not." More From InvestorPlace * 10 Stocks to Buy That Could Be Takeover Targets * 7 S&P 500 Stocks to Buy That Tore Up Earnings * The 10 Best Stocks for 2019 -- So Far Compare Brokers The post Why ContraVir Pharmaceuticals (CTRV) Is Skyrocketing Today appeared first on InvestorPlace.

  • Benzingalast month

    ContraVir Rallies As NASH Drug Shows Efficacy In Preclinical Study

    Shares of the nano-cap, thinly traded biotech  ContraVir Pharmaceuticals Inc (NASDAQ: CTRV ) were trading nearly 150-percent higher Thursday.  What Happened ContraVir, which focuses on therapies for liver ...

  • GlobeNewswirelast month

    ContraVir Pharmaceuticals Sets the Stage for CRV431 Development in NASH with Positive Results from Second Model of Liver Fibrosis

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced findings from a preclinical study where CRV431, a novel cyclophilin inhibitor, significantly decreased the extent of fibrosis in a second animal model of liver fibrosis. Fibrosis, or scarring, of the liver is a hallmark symptom of NASH that results in impaired liver function.

  • GlobeNewswire2 months ago

    ContraVir Pharmaceuticals, Inc. Announces Reverse Stock Split

    ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, announced today a reverse split of its common stock, $0.0001 par value, at a ratio of 1 for 70 effective May 31, 2019 (the “Effective Date”). The reverse stock split is primarily intended to bring the Company into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Capital Market.

  • GlobeNewswire2 months ago

    ContraVir Pharmaceuticals Receives Positive Nasdaq Listing Decision

    ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, announced today that the Nasdaq Hearings Panel has granted the Company’s request for continued listing on The Nasdaq Capital Market, subject to compliance with certain conditions. The Company is diligently working to evidence full compliance with all applicable requirements for continued listing on The Nasdaq Capital Market, in particular the $1.00 minimum bid price requirement.

  • GlobeNewswire3 months ago

    ContraVir Pharmaceuticals to Present at the 2019 ThinkEquity Conference

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, today announced that management will present an update on the Company’s business at the 2019 ThinkEquity Conference on Thursday, May 2, 2019 at 1:30 p.m. Eastern Time in New York, NY. ContraVir is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV).

  • Benzinga3 months ago

    The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 25) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ...

  • GlobeNewswire3 months ago

    ContraVir Pharmaceuticals, Inc. Announces Pricing of $2.14 Million Public Offering

    ContraVir Pharmaceuticals, Inc. (“ContraVir,” the “Company,” “we,” “our” or “us”) (CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, today announced the pricing of a public offering with expected total gross proceeds of approximately $2,140,000 before deducting placement agent fees and other offering expenses payable by the Company. Roth Capital Partners is acting as the lead placement agent for the offering. Brookline Capital Markets, a Division of CIM Securities, LLC is acting as co-placement agent for the offering.

  • GlobeNewswire3 months ago

    ContraVir Pharmaceuticals to Present CRV431 Phase 1 Data at the International Liver Congress™

    EDISON, N.J., April 11, 2019 -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of.

  • Again, Durham pharma loses a drug development partner
    American City Business Journals3 months ago

    Again, Durham pharma loses a drug development partner

    One of Chimerix's development and commercial partners is out, disclosing this week it would be terminating a four-year-old licensing agreement after deciding to drop Chimerix's drug – the second time in less than five years the drug has been abandoned.

  • GlobeNewswire4 months ago

    ContraVir Pharmaceuticals Announces Panel Participation at 31st Annual ROTH Conference

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, today announced that it will participate in a panel at the 31st Annual ROTH Conference, being held in Laguna Niguel, California from March 17-19, 2019.

  • Benzinga6 months ago

    The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs Jan. 15) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Avenue Therapeutics ...

  • GlobeNewswire6 months ago

    ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of liver disease arising from chronic viral infection and non-alcoholic steatohepatitis, announced today that its 2018 Annual Meeting of Stockholders scheduled to be held on January 15, 2019 (the “Annual Meeting”) was adjourned due to a lack of a quorum on the proposals to be approved. The Company intends to set a new record date and will add additional proposals to be voted on at the Annual Meeting. ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted therapies for liver disease arising from chronic hepatitis B, C and D virus (HBV, HVC, HDV) and non-alcoholic steatohepatitis (NASH).